Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-l-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma

详细信息    查看全文

• 作者：Nehad A. Mossad (1)
  Enas H. Mahmoud (1)
  Enas A. Osman (2)
  Sherif H. Mahmoud (3)
  Hend I. Shousha (4)
  
• 关键词：SCCA ; IgM ; Alpha ; l ; fucosidase ; AFP ; Hepatocellular carcinoma
• 刊名：Tumor Biology
• 出版年：2014
• 出版时间：November 2014
• 年：2014
• 卷：35
• 期：11
• 页码：11559-11564
• 全文大小：228 KB
• 参考文献：1. Abdelaziz AO, Elbaz TM, Shousha HI, Ibrahim MM, Elshazli MA, Abdelmaksoud AH, et al. Survival and prognostic factors for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Asian Pac J Cancer Prev. 2014;15(9):3915-0. CrossRef
  2. Freedman S, Edwards K, Ries G, Young L. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER. National Cancer Institute. Bethesda 2006; 06-873.
  3. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138(2):493-02. CrossRef
  4. Giannelli G, Marinosci F, Sgarra C, Lupo L, Dentico P, Antonaci S. Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma. Int J Cancer. 2005; 579-3.
  5. Buccione D, Fatti G, Gallotta A, Loggi E, Roberto G, Testa L, et al. Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis. Gastroenterology. 2012;2:56-1.
  6. Zuin J, Veggiani G, Pengo P, Gallotta A, Biasiolo A, Tono N, et al. Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis. Clin Chem Lab Med. 2010;48(2):217-3. CrossRef
  7. Teofenescu I, Gologan E, Stefanescu G, Balan G. Surveillance of cirrhosis for hepatocellular carcinoma-clinical validation of new serological biomarkers for improved HEBA hepatocellular carcinoma diagnosis. Rev Med Chir Soc Med Nat lasi. 2010;114(1):39-6.
  8. Gameel M, El assaly, N, Madani H, El-Ashry N, Mostafa, Abd El Raof, E and El-Rasky. Evaluation of tumor markers panel in detection of HCC in HCV Egyptian patients and its correlation with AFT M. Research Journal of Medicine and Medical sciences. 2009; 4 (2): 402-10.
  9. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-. CrossRef
  10. Cordero O, Ana M, Nogueira M, Vicenta S. Cell surface human alpha-L-fucosidase. Eur J Biochem. 2001;268:3321-1. CrossRef
  11. Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E, et al. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer. 2006;119:735-0. CrossRef
  12. Dengnier Y, David V, Brissot P, Leray G, Blayau M, Le Gall JY. Serum alpha-L-fucocidase: a new marker for the diagnosis of primary hepatocellular carcinoma. Hepatology. 1984;4:889-2. CrossRef
  13. Hutchinson WL, Johnson PJ, Du MQ, Williams R. Serum and tissue alpha-L-fucosidase activity in the pre-clinical and clinical stages of hepatocellular carcinoma. Clin Sci (Lond). 1991;81(2):177-2.
  14. Wang J, Cao E. Rapid kinetic rate assay of the serum α-L-fucosidase in patients with hepatocellular carcinoma by using a novel substrate. Clinica Chimica Acta. 2004; (347):103-09.
  15. El-Shahawia M, Othmanb A, El-Houseinic M, Nashedd B, Elsofyd M. Spectrofluorimetric method for measuring the activity of the enzyme-l-fucosidase using the ion associate of 2-chloro-4-nitro phenol-rhodamine-B. Talanta. 2009; 15; 80 (1):19-3.
  16. Giardina G, Matarazzo M, Morante R, Lucariello A, Varriale A, Gulidasole V, et al., Serum alpha-L-fucosidase activity and early detection of hepatocellular carcinoma. Cancer. 1998; (83) 2468-74.
  17. Cuer M, Barnier A, de La Salmoniere P, Durand G, and Seta N. Fluorimetric measurement of plasma alpha-L-fucosidase activity with a centrifugal analyzer: reference values in a healthy French adult population. Clin Chem. 2000; (46) 560a-70a.
  18. Montaser MF, Sakr MA, Khalifa MO. Alpha-l-fucosidase as a tumour marker of hepatocellular carcinoma. Arab J Gastroenterol. 2012;13(1):9-3. CrossRef
  19. Malaguarnera G, Giordano M, Paladina I, Berretta M,
• 作者单位：Nehad A. Mossad (1)
  Enas H. Mahmoud (1)
  Enas A. Osman (2)
  Sherif H. Mahmoud (3)
  Hend I. Shousha (4)
  
  1. Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
  2. Clinical and Chemical Pathology Department, Theodor Bilharz Research Institute (TBRI), Cairo, Egypt
  3. Endemic Hepatogastroenterology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
  4. Endemic Hepatogastroenterology Department, Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt
  
• ISSN：1423-0380

文摘

Hepatocellular carcinoma (HCC) surveillance lacks a reliable biomarker. Alpha-fetoprotein (AFP) is the most widely used. However, not all HCCs secrete AFP. AFP may be elevated with cirrhosis in the absence of HCC. Serum alpha-l-fucosidase (AFU) and squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IgM) were found to be useful markers in diagnosing HCC. SCCA-IgM and AFU were assessed by ELISA technique; AFP was measured by enzyme chemiluminescence in serum of 40 patients with HCC, 30 patients with liver cirrhosis, and 20 healthy control participants to compare their accuracy in early diagnosis of HCC. Serum SCCA-IgM and AFU levels were significantly elevated in HCC group compared to cirrhotic group (P value--.001 and IgM was 233?AU/ml with sensitivity 87.5?% and specificity 66?% and for AFU was 25?U/L with sensitivity 87.5?% and specificity 98?%. AFP cutoff value was 48?ng/mL with sensitivity of 70?% and specificity of 53.3?%. The simultaneous determination of AFP and SCCA-IgM activity increased the sensitivity to 92.5?% and specificity to 62.1?%. There were positive significant correlations between SCCA-IgM and each of AFU (r--.296, P--.005) and AFP (r--.284, P--.007) and no correlation between AFP and AFU. All markers did not correlate with the tumor size or affected by the Child score. The significant difference between SCCA-IgM and AFU levels among HCC and cirrhotic patients suggests their use as potential diagnostic tools and allows identifying a new group of HCC patients even in the absence of elevated AFP.